AM-2233 powder was developed by Alexandros Makriyannis at the University of Connecticut and Andrew N Gifford at Brookhaven National Laboratory. AM-2233 is used mainly in order to visualize the distribution of CB1 receptors but has also been discovered to be a substitute for THC, as showed in research with rats. The efficacy of AM-2233 is less strong than that of JWH-018, but stronger than that of WIN-55. Generally AM 2233 targets both the CB1 and CB2 receptors. AM-2233 can help with mapping of brain signals, by ensuring a better distribution via the receptors. AM-2233 was originally developed with this purpose in mind, but is also known for its strong stimulation of the cannabinoid receptors.
IUPAC name: 1-[(N-methylpiperidin-2-yl)methyl]-3-(2-iodobenzoyl)indole
Purity: 99% min
Appearance: white powder
AM-2233 is a chemical for research purposes and should only be used for this purpose. AM-2233 is not sold for human consumption.